Therapeutic efficacy of allogeneic hematopoietic stem cell transplantation in children with chronic myelogenous leukemia
JIANG Hua, HU Wen-Ting, CHEN Jing, LUO Chang-Ying, WANG Jian-Min, ZHOU Min, YE Qi-Dong, TANG Yan-Jing, LUO Cheng-Juan
Department of Hematology/Oncology, Shanghai Children′s Medical Center, Medical School, Shanghai Jiaotong University, Shanghai 200127, China. jiang_hua18@yahoo.com.cn
Abstract OBJECTIVE: To investigate the therapeutic efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in children with chronic myelogenous leukemia (CML), and to analyze the possible prognostic factors.MethodsThe clinical data of 20 children with CML who had received allo-HSCT was analyzed retrospectively to investigate possible prognostic factors, including age, sex, interval between diagnosis and transplantation, HLA matching between donors and recipients, illness status on transplantation and acute and chronic graft-versus-host disease (GVHD).ResultsAt the end of follow-up, 13 of the 20 treated children had disease-free survival (DFS) and the rest (7 cases) died. Four died of severe acute GVHD, two of chronic GVHD and its complications, and one of relapse after transplantation. The three-year DFS was (64.6±1.1%). As shown by the univariate analysis, age was the most important prognostic factor in children with CML who had received allo-HSCT (P0.05). The multivariate logistic regression analysis also confirmed age as the only prognostic factor (P<0.01). Severe acute and/or chronic GVHD was the most important cause of patient death. 10/10 HLA-matched donors could improve the transplantation outcome.ConclusionsAllo-HSCT is an effective treatment for children with CML. To improve the prognosis and treatment outcome, children with CML aged over 10 years should receive allo-HSCT as early as possible. 10/10 HLA-matched donors are preferred in allo-HSCT and GVHD should be prevented.
JIANG Hua,HU Wen-Ting,CHEN Jing et al. Therapeutic efficacy of allogeneic hematopoietic stem cell transplantation in children with chronic myelogenous leukemia[J]. CJCP, 2013, 15(1): 19-24.
JIANG Hua,HU Wen-Ting,CHEN Jing et al. Therapeutic efficacy of allogeneic hematopoietic stem cell transplantation in children with chronic myelogenous leukemia[J]. CJCP, 2013, 15(1): 19-24.
［1］Castro-Malaspina H, Schaison G, Briere J, Passe S, Briere J, Pasquier A, et al. Philadelphia chromosome-positive chronic myelocytic leukemia in children. Survival and prognostic factors［J］. Cancer, 1983, 52(4): 721-727.
3.0.CO;2-X target="_blank">
［6］Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading［J］. Bone Marrow Transplant, 1995, 15(6): 825-828.
［2］Altman AJ. Chronic leukemias of childhood［J］. Pediatr Clin North Am, 1988, 35(4): 765-787.
［7］Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report［J］. Biol Blood Marrow Transplant, 2005, 11(12): 945-956.
［3］Lee JW, Chung NG. The treatment of pediatric chronic myelogenous leukemia in the imatinib era［J］. Korean J Pediatr, 2011, 54(3): 111-116.
［8］Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K, et al. Choice of pretreatment treatment and timing of transplants for chronic myelogenous leukemia in chronic phase［J］. Blood, 1993, 82(7): 2235-2238.
［4］Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia［J］. Semin Hematol, 1988, 25(1): 49-61.
［9］Gratwohl A, Hermans J, Apperley J, Arcese W, Bacigalupo A, Bandini G, et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia［J］. Blood, 1995, 86(2): 813-818.
［10］Sharathkumar A, Thornley I, Saunders EF, Calderwood S, Freedman MH, Doyle J. Allogenic bone marrow transplantation in children with chronic myelogenous leukemia［J］. J Pediatr Hematol Oncol, 2002, 24(3): 215-219.
［6］Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading［J］. Bone Marrow Transplant, 1995, 15(6): 825-828.
［11］Thomas ED, Clift RA, Fefer A, Appelbaum FR, Beatty P, Bensinger WI, et al. Marrow transplantation for the treatment of chonic myelogenous leukemia［J］. Ann Intern Med, 1986, 104(2): 155-163.
［7］Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report［J］. Biol Blood Marrow Transplant, 2005, 11(12): 945-956.
［12］Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, longterm data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) ［J］. Haematologica, 2006, 91(4): 513-521.
［8］Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K, et al. Choice of pretreatment treatment and timing of transplants for chronic myelogenous leukemia in chronic phase［J］. Blood, 1993, 82(7): 2235-2238.
［13］Unal S, Fidan G, Tavil B, Cetin M, Cetinkaya DU. Allogeneic hematopoietic stem cell transplantation in pediatric chronic myelogenous leukemia cases: Hacettepe experience［J］. Pediatr Transplant, 2007, 11(6): 645-649.
［9］Gratwohl A, Hermans J, Apperley J, Arcese W, Bacigalupo A, Bandini G, et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia［J］. Blood, 1995, 86(2): 813-818.
［10］Sharathkumar A, Thornley I, Saunders EF, Calderwood S, Freedman MH, Doyle J. Allogenic bone marrow transplantation in children with chronic myelogenous leukemia［J］. J Pediatr Hematol Oncol, 2002, 24(3): 215-219.
［14］Cwynarski K, Roberts IA, Iacobelli S, van Biezen A, Brand R, Devergie A, et al. Stem cell transplantation for chronic myeloid leukemia in children［J］. Blood, 2003, 102(4): 1224-1231.
［11］Thomas ED, Clift RA, Fefer A, Appelbaum FR, Beatty P, Bensinger WI, et al. Marrow transplantation for the treatment of chonic myelogenous leukemia［J］. Ann Intern Med, 1986, 104(2): 155-163.
［15］Rubio MT, Moreira-Teixeira L, Bachy E, Bouillié M, Milpied P, Coman T,et al.Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival［J］. Blood, 2012, 120(10): 2144-2154.
［16］Suttorp M, Yaniv I, Schultz KR.Controversies in the treatment of CML in children and adolescents: TKIs versus BMT?［J］. Biol Blood Marrow Transplant, 2011, 17(1 Suppl): S115-S122.
［12］Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, longterm data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) ［J］. Haematologica, 2006, 91(4): 513-521.
［13］Unal S, Fidan G, Tavil B, Cetin M, Cetinkaya DU. Allogeneic hematopoietic stem cell transplantation in pediatric chronic myelogenous leukemia cases: Hacettepe experience［J］. Pediatr Transplant, 2007, 11(6): 645-649.
［14］Cwynarski K, Roberts IA, Iacobelli S, van Biezen A, Brand R, Devergie A, et al. Stem cell transplantation for chronic myeloid leukemia in children［J］. Blood, 2003, 102(4): 1224-1231.
［15］Rubio MT, Moreira-Teixeira L, Bachy E, Bouillié M, Milpied P, Coman T,et al.Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival［J］. Blood, 2012, 120(10): 2144-2154.
［16］Suttorp M, Yaniv I, Schultz KR.Controversies in the treatment of CML in children and adolescents: TKIs versus BMT?［J］. Biol Blood Marrow Transplant, 2011, 17(1 Suppl): S115-S122.
